Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Balsalazide.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

2.

5-aminosalicylic acid agents for prevention of recurrent diverticulitis: A systematic review and meta-analysis.

Urushidani S, Kuriyama A, Matsumura M.

J Gastroenterol Hepatol. 2018 Jan;33(1):12-19. doi: 10.1111/jgh.13846.

PMID:
28623877
3.

Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.

Kim SL, Kim SH, Park YR, Liu YC, Kim EM, Jeong HJ, Kim YN, Seo SY, Kim IH, Lee SO, Lee ST, Kim SW.

Mol Cancer Res. 2017 Feb;15(2):141-151. doi: 10.1158/1541-7786.MCR-16-0101. Epub 2016 Nov 14.

4.

Sustainable Synthesis of Balsalazide and Sulfasalazine Based on Diazotization with Low Concentrations of Nitrogen Dioxide in Air.

Hofmann D, Gans E, Krüll J, Heinrich MR.

Chemistry. 2017 Mar 23;23(17):4042-4045. doi: 10.1002/chem.201605359. Epub 2017 Jan 25.

PMID:
28054726
5.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Wang Y, Parker CE, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 May 9;(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Review.

PMID:
27158764
6.

Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.

Do EJ, Hwang SW, Kim SY, Ryu YM, Cho EA, Chung EJ, Park S, Lee HJ, Byeon JS, Ye BD, Yang DH, Park SH, Yang SK, Kim JH, Myung SJ.

J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. doi: 10.1111/jgh.13280.

PMID:
26711554
7.

Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells.

Kim HY, Kim SL, Park YR, Liu YC, Seo SY, Kim SH, Kim IH, Lee SO, Lee ST, Kim SW.

Intest Res. 2015 Jul;13(3):233-41. doi: 10.5217/ir.2015.13.3.233. Epub 2015 Jun 9.

8.

On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid.

Sousa T, Yadav V, Zann V, Borde A, Abrahamsson B, Basit AW.

J Pharm Sci. 2014 Oct;103(10):3171-5. doi: 10.1002/jps.24103. Epub 2014 Aug 4.

PMID:
25091594
9.

Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.

Dhaneshwar SS.

World J Gastroenterol. 2014 Apr 7;20(13):3564-71. doi: 10.3748/wjg.v20.i13.3564. Review.

10.

Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.

Coman RM, Glover SC, Gjymishka A.

Expert Rev Clin Immunol. 2014 May;10(5):667-75. doi: 10.1586/1744666X.2014.902313. Epub 2014 Apr 1. Review.

PMID:
24689504
11.

Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.

Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S.

Eur J Clin Pharmacol. 2014 Jun;70(6):709-17. doi: 10.1007/s00228-014-1660-7. Epub 2014 Mar 11.

12.

Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Sim E, Abuhammad A, Ryan A.

Br J Pharmacol. 2014 Jun;171(11):2705-25. doi: 10.1111/bph.12598. Review.

13.

Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials.

Sun H, Lee JJ, Papadopoulos EJ, Lee CS, Nelson RM, Sachs HC, Rodriguez WJ, Mulberg AE.

J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):12-7. doi: 10.1097/MPG.0000000000000186.

PMID:
24121142
14.
15.

5-ASA induced recurrent myopericarditis and cardiac tamponade in a patient with ulcerative colitis.

Sonu I, Wong R, Rothenberg ME.

Dig Dis Sci. 2013 Aug;58(8):2148-50. doi: 10.1007/s10620-013-2566-4. Epub 2013 Jan 30. No abstract available.

PMID:
23361575
16.

A Case of Balsalazide-Induced Limited Form of Granulomatosis with Polyangiitis with Bronchiolitis Obliterans Organizing Pneumonia-like Variant in Ulcerative Colitis.

Kang SM, Jang YR, Yoon HH, Kim S, Kim EY, Ha SY, Park JW.

Tuberc Respir Dis (Seoul). 2012 Mar;72(3):323-7. doi: 10.4046/trd.2012.72.3.323. Epub 2012 Mar 31.

17.
18.

Extended-release mesalamine granules for ulcerative colitis.

Love BL, Miller AD.

Ann Pharmacother. 2012 Nov;46(11):1529-36. doi: 10.1345/aph.1R171. Epub 2012 Oct 31. Review.

PMID:
23115226
19.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD000544.

PMID:
23076890
20.

Systematic review of medical therapy to prevent recurrent diverticulitis.

Unlü C, Daniels L, Vrouenraets BC, Boermeester MA.

Int J Colorectal Dis. 2012 Sep;27(9):1131-6. doi: 10.1007/s00384-012-1486-7. Epub 2012 May 11. Review.

PMID:
22576905

Supplemental Content

Loading ...
Support Center